Articles from Atom Therapeutics Co., Ltd.

Atom Therapeutics, an innovative clinical-stage biotechnology company focused on the discovery and development of novel therapies for metabolic, inflammatory, and cardiovascular diseases, today announced that the first patient has been successfully dosed in its Phase 2 clinical trial evaluating lingdolinurad (ABP-671), for treatment of chronic kidney disease (CKD) with hyperuricemia. This Phase 2 clinical trial is being conducted in Australia and China.